Press Releases

Research and Markets: Key Findings from Treatment Algorithms: Multiple Sclerosis


DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Multiple Sclerosis" to their offering.

Until recently, the MS market comprised a stable mix of time-tested disease-modifying therapies with established roles in treatment several interferon-beta (IFN-ß) products, glatiramer acetate (Teva's Copaxone), and natalizumab (Biogen Idec/Elan's Tysabri). Today, however, the MS market stands at the brink of transformation.

The 2010 launch of fingolimod (Novartis/Mitsubishi Tanabe Pharma's Gilenya)the first orally administered disease-modifying drug for MSmarks the beginning of a new era in MS treatment that will feature enhanced treatment choice, increasingly complex decision-making for prescribers, and an invigorated push toward individualized treatment.

In the coming years, neurologists will strive to integrate new therapeutic options with unique risk/benefits into an ingrained treatment paradigm that favors long-term safety and clinical experienceeven at the expense of more-robust efficacy.

Key Topics Covered:

1. Background

a) Publication Update

b) Report Contents and Features

c) Current Practice Guidelines

d) Key U.S. Market Events Influencing Treatment Selection

2. Key Findings for Newly Diagnosed Patients

a) Executive Summary

b) Graphical Views

3. Key Findings for Recently Treated Patients

a) Executive Summary

b) Graphical Views

4. Key Findings by Product

a) Copaxone

b) Avonex

c) Rebif

d) Betaseron/Extavia

e) Tysabri

f) Gilenya

5. Appendix: Methodology

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Source: Research and Markets